David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding needs. Click for my LPTX stock update.

Thoracoabdominal esophagectomy was performed for esophageal tumors and for esophagogastric junction tumors extending into the esophagus. For esophagogastric junction tumors, a thoracoabdominal ...

In gastric cancer, Keytruda is approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic ...

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and ...

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up ...

In a remarkable medical achievement, an 86-year-old man presented to Manipal Hospital Vijayawada with a long-standing history ...

Three-fourths of patients with unresectable gastroesophageal cancer converted to resectable and had clear margins after treatment with a chemoimmunotherapy combination, a small Chinese study showed.

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): ...

“Whereas in Malaysia, screening is still primarily focused on individuals with gastric issues, a strong family history of ...